Emerging data suggest that SBRT may be comparable with surgery for definitive treatment of stage I NSCLC in certain patients. When is one approach preferred and in whom?

Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at AD/PD™ 2025 International ...

(the "Company") announced that the Company has received a clinical trial notice approving the investigational new drug application for a radionuclide-drug conjugate (RDC) drug SKB107 (formerly TBM-001 ...

Neoadjuvant chemoimmunotherapy is associated with significantly improved survival outcomes compared with standard ...

Reflections on a recent NEJM publication highlight the importance of identifying and addressing the pathologic process of ...